Medidata Solutions, Inc. (NASDAQ:MDSO) has earned an average rating of “Buy” from the thirteen ratings firms that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and ten have given a buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $81.36.

Several research analysts have recently issued reports on the stock. Morgan Stanley set a $74.00 target price on shares of Medidata Solutions and gave the stock a “buy” rating in a report on Wednesday, June 14th. BidaskClub cut shares of Medidata Solutions from a “buy” rating to a “hold” rating in a report on Wednesday, June 14th. Needham & Company LLC restated a “buy” rating and issued a $90.00 target price (up previously from $75.00) on shares of Medidata Solutions in a report on Friday, July 21st. Bank of America Corporation assumed coverage on shares of Medidata Solutions in a report on Tuesday, June 6th. They issued a “buy” rating and a $85.00 target price on the stock. Finally, Piper Jaffray Companies raised their target price on shares of Medidata Solutions to $87.00 and gave the stock an “overweight” rating in a report on Friday, July 7th.

Medidata Solutions (NASDAQ:MDSO) traded up 0.86% during midday trading on Friday, reaching $74.01. 395,472 shares of the company traded hands. The company has a market capitalization of $4.19 billion, a price-to-earnings ratio of 119.56 and a beta of 1.81. Medidata Solutions has a one year low of $46.10 and a one year high of $85.92. The stock’s 50 day moving average is $74.86 and its 200 day moving average is $69.17.

Medidata Solutions (NASDAQ:MDSO) last issued its quarterly earnings results on Tuesday, July 18th. The company reported $0.31 EPS for the quarter, beating analysts’ consensus estimates of $0.28 by $0.03. Medidata Solutions had a net margin of 7.07% and a return on equity of 11.14%. The business had revenue of $137.41 million for the quarter, compared to analysts’ expectations of $134.28 million. During the same period last year, the business earned $0.24 earnings per share. The business’s quarterly revenue was up 19.9% on a year-over-year basis. On average, equities analysts anticipate that Medidata Solutions will post $1.28 earnings per share for the current year.

In other news, COO Michael L. Capone sold 5,000 shares of the firm’s stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $74.53, for a total transaction of $372,650.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 5.80% of the stock is owned by company insiders.

Several large investors have recently modified their holdings of MDSO. BB&T Corp increased its holdings in shares of Medidata Solutions by 7.7% during the first quarter. BB&T Corp now owns 5,775 shares of the company’s stock valued at $333,000 after acquiring an additional 415 shares in the last quarter. Canada Pension Plan Investment Board bought a new position in shares of Medidata Solutions during the first quarter valued at $2,261,000. Great West Life Assurance Co. Can increased its holdings in shares of Medidata Solutions by 6.4% during the first quarter. Great West Life Assurance Co. Can now owns 77,373 shares of the company’s stock valued at $4,463,000 after acquiring an additional 4,665 shares in the last quarter. Eqis Capital Management Inc. increased its holdings in shares of Medidata Solutions by 8.6% during the first quarter. Eqis Capital Management Inc. now owns 5,268 shares of the company’s stock valued at $304,000 after acquiring an additional 419 shares in the last quarter. Finally, Advisors Asset Management Inc. increased its holdings in shares of Medidata Solutions by 80.9% during the first quarter. Advisors Asset Management Inc. now owns 19,317 shares of the company’s stock valued at $1,114,000 after acquiring an additional 8,638 shares in the last quarter. Hedge funds and other institutional investors own 97.53% of the company’s stock.

WARNING: “Medidata Solutions, Inc. (MDSO) Given Average Recommendation of “Buy” by Analysts” was originally published by American Banking News and is the property of of American Banking News. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://www.americanbankingnews.com/2017/09/09/medidata-solutions-inc-mdso-given-average-recommendation-of-buy-by-analysts.html.

Medidata Solutions Company Profile

Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.

Analyst Recommendations for Medidata Solutions (NASDAQ:MDSO)

Receive News & Ratings for Medidata Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.